Sutro Biopharma (NASDAQ:STRO – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.20, Yahoo Finance reports. The business had revenue of $25.71 million for the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative net margin of 74.61% and a negative return on equity of 94.18%.
Sutro Biopharma Trading Up 6.2 %
NASDAQ STRO traded up $0.20 during trading on Wednesday, hitting $3.42. 345,100 shares of the company’s stock were exchanged, compared to its average volume of 884,239. The company has a market cap of $279.72 million, a PE ratio of -1.84 and a beta of 1.22. Sutro Biopharma has a fifty-two week low of $2.01 and a fifty-two week high of $6.13. The stock’s 50 day moving average price is $3.53 and its two-hundred day moving average price is $4.05.
Analyst Ratings Changes
A number of brokerages recently issued reports on STRO. Oppenheimer reissued an “outperform” rating and set a $10.00 price target on shares of Sutro Biopharma in a research report on Wednesday, May 15th. Wedbush reissued an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a report on Tuesday, May 14th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a research note on Wednesday. Finally, Bank of America initiated coverage on shares of Sutro Biopharma in a research note on Wednesday, May 8th. They set a “buy” rating and a $12.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Sutro Biopharma currently has an average rating of “Buy” and an average price target of $12.50.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Read More
- Five stocks we like better than Sutro Biopharma
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Stocks That Could Beat the September Blues
- Do ETFs Pay Dividends? What You Need to Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.